Ex-Novartis Exec Joins Checkpoint Agonist-Focused Biotech

Carolin Barth Is New CEO

 
• By Andrew McConaghie

The Oxford university spin-out MiroBio has a senior leadership team in place, and aims to have its first checkpoint agonists in the clinic in 2022. Scrip spoke to its CEO about its plans.

Oxford Science Park, Fletcher House and Winchester House
Miro Bio is headquartered at Oxford Science Park, UK

More from Dermatological

More from Therapy Areas